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Abstract 
 Low circulating peptide YY (PYY) levels are reported in obese and type II diabetic 
subjects and results from PYY knockout animals suggests that PYY deficiency may have a 
causative role in the etiology of obesity and type 2 diabetes. Here, our aims were to 
determine whether people with a genetic predisposition to developing type 2 diabetes and 
obesity differ from otherwise similar subjects without such family history, in fasting or meal-
related PYY levels, fasting insulin, insulin secretion (HOMA-B) and insulin sensitivity. We also 
investigated whether PYY ablation affects the intrinsic ability of islets to secrete insulin, which 
may be a contributing factor to the hyperinsulinemia observed in PYY knockout mice. 
 Healthy female first-degree relatives of people with type 2 diabetes were matched for 
age, gender and BMI to control subjects but had significantly lower insulin sensitivity 
(p < 0.05). Relatives also had significantly lower fasting serum PYY levels than controls 
(p < 0.05), but their PYY response to a high fat meal (4250 kJ, 73% fat) was not significantly 
different. Fasting PYY level correlated positively with glucose infusion rate (r = 0.713, 
p = 0.002) and fasting adiponectin (r = 0.5, p = 0.02). Islets of Langerhans from PYY knockout 
mice were found to hypersecrete insulin in response to 25 mM glucose (p < 0.05). These data 
demonstrate that lack of PYY enhances insulin secretion from the Islets of Langerhans and 
that low fasting PYY levels are associated with insulin resistance in humans. Together, these 
findings suggest that low circulating levels of PYY could contribute to hyperinsulinemia and 
insulin resistance, and possibly contribute to subsequent development of obesity and type 2 
diabetes. 
 
Abbreviations 
  AUC, area under the curve; BMI, body mass index; DPPIV, dipeptidyl peptidase-IV; DXA, dual-energy X-ray 
absorptiometry; GIR, glucose infusion rate; HOMA-B, HOMA-Beta; PYY, peptide YY; RIA, radioimmunoassay 
 
 
1. Introduction 
 Peptide YY (PYY) is an enteroendocrine hormone implicated in the pathogenesis of 
human and rodent obesity (Batterham et al., 2002, Roth et al., 2005 and Alvarez Bartlolome 
et al., 2002). It is a member of the neuropeptide Y family, and is secreted from the L cells of 
the gastrointestinal tract in response to food (Batterham et al., 2002). There are two 
endogenous forms of PYY: PYY1-36 and PYY3-36. The latter is produced by removal of two 
N terminal amino acids from the full-length form by an enzyme called dipeptidyl peptidase-IV 
(DPPIV) ( Renshaw and Batterham, 2005). 
 In humans, PYY3-36 is the main form produced postprandially, contributing to 
approximately 63% of circulating PYY in the fed state and only 37% in the fasting state 
(Grandt et al., 1994). Circulating PYY levels increase within 15 min of ingesting a meal, peak 
at approximately 60 min and remain elevated for up to 6 h Adrian et al., 1985 and Adrian et 
al., 1985. Dietary fat is the most potent stimulant of PYY release Adrian et al., 
1985 and Adrian et al., 1985. 
 Recent studies have investigated the effects of PYY3-36 on satiety, food intake and 
body weight in animals and humans (Batterham et al., 2003 and Batterham et al., 2002). It 
appears that PYY3-36 acts on the arcuate nucleus in the hypothalamus to reduce food intake 
and body weight, possibly via inhibiting NPY neurons and stimulating POMC expressing 
neurons via Y2 receptors (Batterham et al., 2002). It has also been demonstrated that PYY3-
36 acts via regions of the brainstem, the area postrema and nucleus tractus solitarius, to 
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reduce food intake by inducing an aversive response (Halatchev and Cone, 2005). 
 Since PYY reduces food intake and body weight, and because some studies report 
reduced circulating PYY concentrations in obese people, it is hypothesized that low 
circulating PYY levels are an etiological factor in the development of obesity. Indeed, obese 
children (Roth et al., 2005) and morbidly obese patients (Alvarez Bartlolome et al., 2002) 
have significantly lower fasting PYY levels than non-obese subjects. However, whether 
circulating PYY levels contribute to or result from obesity cannot be determined from cross-
sectional studies in subjects already widely different in adiposity. One study reported lower 
postprandial PYY levels in obese compared to lean adolescents, with no difference in fasting 
PYY levels between groups (Stock et al., 2005), and another found no differences in fasting 
PYY levels or PYY secretion in response to oral glucose between lean and obese people, 
also contradicting previous reports that fasting PYY was inversely correlated with BMI (Kim et 
al., 2005). Interestingly, this study also highlighted that females produce a larger PYY 
response to a meal than male participants (Kim et al., 2005). 
 Human and animal studies suggest that low circulating levels of PYY may be involved 
in the etiology of type 2 diabetes and associated obesity. Intravenous infusion of PYY3-36 for 
several hours in diet-induced insulin-resistant mice enhanced insulin sensitivity, as assessed 
by hyperinsulinemic-euglycemic clamp (van den Hoek et al., 2004). Moreover, a 4-week 
subcutaneous infusion of PYY3-36 by osmotic pump in diabetic fatty Zucker rats also 
improved glycemic indices (HbA1c and fructosamine) (Pittner et al., 2004). Recently it has 
been demonstrated that diet-induced obese mice and rats that were administered PYY3-36 
subcutaneously for 28 days consecutively displayed increased glucose tolerance compared 
to vehicle-treated animals, although this was not statistically significant (Vrang et al., 2006). 
Diet- induced obese rats administered the highest dose of PYY3-36 showed significantly 
lower fasting serum insulin levels than fasted vehicle-treated mice. Moreover, PYY3-36 dose-
dependently decreased the area under the insulin response curves after glucose injection in 
diet-induced obese rats (Vrang et al., 2006). Together these animal studies imply an 
important role of PYY on both insulin sensitivity and glycemic control. Genetic linkage studies 
suggest a common Ag72Thr variant in the human PYY gene is modestly associated with type 
2 diabetes (Torekov et al., 2005). Furthermore, the circulating PYY response to a meal was 
blunted in people with type 2 diabetes compared to BMI-matched control subjects, although 
fasting PYY levels were significantly increased in subjects with diabetes (English et al., 2004). 
Nonetheless, confusion still exists as to whether low fasting and/or meal-induced levels of 
PYY are a cause or a consequence of type 2 diabetes or associated obesity. 
 To study the potential etiological role of PYY in the development of obesity or type 2 
diabetes before the disease developed, we investigated fasting and meal-induced circulating 
PYY levels in healthy women who have first degree relatives with type 2 diabetes mellitus. 
These women have a strong genetic predisposition to type 2 diabetes and obesity. Two out of 
three such relatives eventually develop diabetes by glucose tolerance testing (Kahn et al., 
1969), and the majority of people with type 2 diabetes become overweight or obese 
(Drivsholm and Olivarius, 2005). The relatives were compared with a matched control group 
without any family history of diabetes. Any detectable differences between groups (before 
excess adiposity or type 2 diabetes developed) could imply low PYY plays a part in the 
development of obesity and/or the pathophysiology of type 2 diabetes. 
 Following our previous observations that PYY ablation in mice leads to 
hyperinsulinemia in vivo, particularly in response to a bolus injection of glucose (Boey et al., 
2006), our aims were to address whether hyperinsulinemia in PYY knockout animals was a 
result of a change in the intrinsic ability of their islets to secrete insulin. Here, we isolated 
islets from PYY knockout and wild type animals and evaluated insulin secretion and beta cell 
function under basal, moderate and high concentrations of glucose in order to determine the 
overall effect of PYY deficiency on islet function (Boey et al., 2006). Our hypothesis was that 
there is a predisposing defect in PYY secretion prior to the development of type 2 diabetes, 
which influences the later increased adiposity. This defect may also contribute to glucose 
intolerance, possibly through effects on insulin secretion and/or insulin sensitivity. 
 
2. Research design and methods 
2.1. Subjects 
 A total of 21 healthy, sedentary, non-smoking female volunteers, aged 20–45 years,  
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without cardiovascular disease, hypertension, endocrine disorders, or dyslipidemia were 
recruited. The relative group (n = 12) had two first-degree relatives (at least one parent) with 
type 2 diabetes, or one first-degree relative and a personal history of gestational diabetes, (as 
previously described ( Kriketos et al., 2004 and Kriketos et al., 2005)). The control group 
(n = 9) had no family history of diabetes. All were premenopausal and not pregnant at the 
time of the study. Subjects were studied at the follicular phase stage of the menstrual cycle. 
All subjects had normal glucose tolerance by oral glucose tolerance testing. The study 
received approval by the St Vincent’s Hospital Human Research Ethics Committee and all 
subjects provided written informed consent. 
 
3. Protocol 
 Subject characteristics (weight, BMI, percent body fat, abdominal fat, and fasting 
serum levels of insulin, glucose, and adiponectin) were determined as described previously 
(Kriketos et al., 2004 and Kriketos et al., 2005). Percent body fat was determined by whole 
body DXA (Lunar DPX-Lunar Radiation Corporation, Madison, Wisconsin, USA, software 
version 1.35). Serum insulin and adiponectin were measured by radioimmunoassays (Linco, 
St Charles, MO). Adiponectin levels were measured in light of previous findings that plasma 
adiponectin levels strongly correlate with whole body insulin sensitivity (Weyer et al., 2001). 
Visceral and subcutaneous abdominal fat was determined by four T1 weighted axial 
abdominal MRI scans (5 mm thickness) between L1/2 and L4/5 intervertebral discs using 
imaging software NIH Image 1.62 (National Institute of Health, Bethesda, MD). Glucose 
tolerance was measured by a 75-g oral glucose tolerance test, and insulin sensitivity was 
assessed by euglycaemic-hyperinsulinemic clamp (Kriketos et al., 2004). Clamps were 
performed 1-week before the meal test. Briefly, one cannula was placed in an antecubital vein 
for infusion of insulin (Novo Nordisk, NSW, Australia) and glucose (Baxter, NSW, Australia). A 
second cannula was placed retrograde in a dorsal vein of the contralateral hand for blood 
withdrawal, and the hand was placed in a heating pad. Insulin was infused at 50 mU/m2/min 
and arterialized glucose was measured at 10-min intervals (YSI 2300, Yellow Springs, OH), 
and a variable infusion of exogenous glucose was given to maintain glucose concentrations 
at 5 mmol/L. 
 As high fat gives greater PYY stimulus and in order to evaluate the postprandial PYY 
response to a meal, subjects were fasted for a minimum of 10 h before consuming a meal 
containing ∼80 g of dietary fat with an energy content of 4250 kJ. The meal was composed of 
19 g carbohydrate, 40 g saturated fat and 47 g protein consisting of cheese (44 g), beef 
(100 g), fried egg (118 g), copha (coconut oil; 8 g), cracker biscuit (12.5 g) cream (fat > 48%) 
(25 g), strawberries (130 g) and macadamia nuts (20 g); total 458 g (Peake et al., 2003). PYY 
is secreted in proportion to calories ingested, particularly calories from fat, so we therefore 
used a high calorie meal that was high in fat to stimulate PYY output, in order to magnify 
differences between groups. The meal was prepared on the same morning and consumed 
within 20 min, accompanied by 600 mL of water. Blood was collected via an antecubital vein 
10 min and 0 min prior to the meal and at 30, 60, 120 and 360 min after completion of meal. 
Complete blood samples in response to the meal were available on a subset of subjects (8 
controls, 9 relatives). 
 
4. PYY radioimmunoassay 
 PYY was measured as follows: serum samples were frozen immediately at −80 °C. 
Aprotinin was added immediately on thawing (0.3 TIU aprotinin/ml serum). Serum aliquots 
(500 µL) were acidified with 1% TFA and then loaded onto Sep-pak C18 columns 
(Phenomenex Torrance CA USA) that had been equilibrated with 60% acetonitrile in 1% TFA 
followed by 1% TFA in water. Columns were washed twice with 1% TFA in water and the 
peptide was eluted with 60% acetonitrile in 1% TFA. Samples were air-dried overnight, frozen 
in liquid nitrogen and freeze-dried. The lyophilised powder was resuspended in the buffer 
provided in the Human PYY radioimmunoassay kit (Phoenix Pharmaceuticals, Belmont, 
California, USA). 
 Total human PYY including both PYY1-36 and PYY3-36 was measured by a 
commercially available radioimmunoassay kit containing 125I-labelled human PYY and 
antibody against human PYY that exhibits 100% cross-reactivity for both forms of PYY. 
 
 
5. Islet studies 
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 All research and animal care procedures were approved by the Garvan Institute/St 
Vincent’s Hospital Animal Experimentation Ethics Committee. Wild type and PYY−/− animals 
generated as described previously (Boey et al., 2006) were group-housed and fed ad libitum 
under conditions of controlled temperature (22 °C) and illumination (12 h light cycle, light 
onset at 7.00 am). Four 13-week old wild type and 4 age-matched PYY knockout mice were 
anaesthetized and their islets of Langerhans isolated with liberase (Roche Diagnostics, 
Indianapolis, IN, USA) digestion of the pancreas followed by purification with a Ficoll–Paque 
density gradient (Amersham Biosciences, Uppsala, Sweden), as described elsewhere 
(Kjorholt et al., 2005). Two to three batches of 5 islets were incubated in Krebs Ringer buffer 
supplemented with 2.8, 16.7 or 25 mM glucose for 1 h at 37 °C. Insulin was measured in an 
aliquot of the buffer by radioimmunoassay (Linco Research, St Charles, Missouri, USA) with 
rat insulin standard. 
 
6. Statistical analysis 
 Data are expressed as means ± SEM unless otherwise stated. Statistical analyses 
were performed using STATVIEW 5 (SAS Institute Inc., Cary NC). Subjects’ physical 
characteristics were compared between groups using one-way ANOVA. Postprandial 
responses to the meal were analysed by repeated measures ANOVA, and as area under the 
curve (AUC) by the trapezoidal method. Insulin secretion was estimated using the 
homeostasis model assessment, HOMA-Beta (HOMA-B), which approximates the steady 
state beta cell function for the duration of the euglycaemic-hyperinsulinemic clamp, using the 
fasting serum glucose and insulin levels (Matthews et al., 1985). Correlations between 
continuous variables were examined by simple linear regression analyses. A p-value of 0.05 
or less was considered significant. 
 
7. Results 
7.1. Comparison of adiposity, metabolic parameters, serum adiponectin and PYY levels in 
controls and diabetic relatives 
 There were no significant differences between controls and relatives with respect to 
age or BMI (Table 1). Visceral fat was similar between groups, although relatives had non-
significantly higher subcutaneous body fat (Table 1). Fasting insulin, glucose and adiponectin 
levels were also comparable between controls and relatives (Table 1). As we have shown 
previously, relatives were significantly less insulin sensitive than the controls, indicated by the 
significantly lower clamp glucose infusion rate (GIR) (Table 1) (Kriketos et al., 2004). Fasting 
PYY was significantly lower in the relative group compared to controls (Table 1). 
 
 
 
 
 
7.2. Serum PYY response after a high fat meal in controls and diabetic relatives 
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by radioimmunoassay (Linco Research, St Charles, Mis-
souri, USA) with rat insulin standard.
6. Statistical analysis
Data are expressed as means§SEM unless otherwise
stated. Statistical analyses were performed using STAT-
VIEW 5 (SAS Institute Inc., Cary NC). Subjects’ physi-
cal characteristics were compared between groups using
one-way ANOVA. Postprandial responses to the meal
were analysed by repeated measures ANOVA, and as
area under the curve (AUC) by the trapezoidal method.
Insulin secretion was estimated using the homeostasis
model assessment, HOMA-Beta (HOMA-B), which
approximates the steady state beta cell function for the
duration of the euglycaemic-hyperinsulinemic clamp,
using the fasting serum glucose and insulin levels (Mat-
thews et al., 1985). Correlations between continuous
variables were examined by simple linear regression
analyses. A p-value of 0.05 or less was considered signiW-
cant.
7. Results
7.1. Comparison of adiposity, metabolic parameters, 
serum adiponectin and PYY levels in controls and diabetic 
relatives
There were no signiWcant diVerences between controls
and relatives with respect to age or BMI (Table 1).
Visceral fat was similar between groups, although rela-
tives had non-signiWcantly higher subcutaneous body fat
(Table 1). Fasting insulin, glucose and adiponectin levels
were also comparable between controls and relatives
(Table 1). As we have shown previously, relatives were
signiWcantly less insulin sensitive than the controls, indi-
cated by the signiWcantly lower clamp glucose infusion
rate (GIR) (Table 1) (Kriketos et al., 2004). Fasting PYY
was signiWcantly lower in the relative group compared to
controls (Table 1).
7.2. Serum PYY response after a high fat meal in controls 
and diabetic relatives
While the PYY response to a meal appeared Xatter in
the relatives versus controls (Fig. 1), the diVerence was
not statistically signiWcant when assessed with repeated
measures ANOVA (pD0.13). PYY area under the curve
was not diVerent between the groups (pD 0.34).
7.2.1. Serum PYY levels in relation to GIR, fasting 
insulin, HOMA-B and serum adiponectin levels
There were no signiWcant relationships between
fasting serum PYY and BMI or other anthropometric
indices in the overall group (% fat and BMI are shown
in Fig. 2). Fasting serum PYY was signiWcantly related
to insulin sensitivity (GIR) (Fig. 2a). Moreover, there
was an inverse relationship between fasting serum
PYY and fasting serum insulin (Fig. 2b). There was
also an inverse relationship between fasting serum
PYY and HOMA-B (Fig. 2c) and a positive relation-
ship with serum adiponectin (Fig. 2d). No correlations
were observed between the area under the curve PYY
and the area under the curve insulin response to a
meal.
There was one relative subject with a BMI of 32 and
low PYY levels in comparison to the rest of the relatives
group (Fig. 2f). Correlation analyses were repeated with
Table 1
Physical characteristics of controls and relatives of people with type 2
diabetes
Data is expressed as mean§ SD.
a Log transformed.
Controls Relatives p-value
N 9 12
Age (y) 28.9§ 2.5 29.4§ 2.2 0.88
Weight (kg) 60.2§ 2.3 69.6§ 5.0 0.14
BMI (kg/m2) 22.0§ 1.0 25.5§ 1.6 0.09
Body fat (%) 31§ 3 37§ 3 0.11
Total abdominal fat (L) 2.0§ 0.5 2.8§ 0.4 0.24
Visceral fat (L) 0.4§ 0.1 0.5§ 0.1 0.37
Subcutaneous fat (L) 1.6§ 0.5 2.3§ 0.4 0.23
GIR (!mol/kgFFM/min) 61.0§ 5.6 45.0§ 4.6 0.04
HOMA-beta 173§ 24 192§ 16 0.52
Fasting PYY (pmol/L) 30.1§ 5.7 17.5§ 5.7 0.05a
Fasting insulin (mU/!l) 8.6§ 1.2 12.4§ 2.0 0.15
Fasting glucose (mM) 4.6§ 0.1 4.8§ 0.2 0.35
Fasting adiponectin (!g/ml) 21.9§ 1.9 18.4§ 2.2 0.26
Fig. 1. PYY levels in response to a high fat meal in 8 control subjects
(control) and 9 relatives of people with type 2 diabetes (relative) for up
to 6 h.
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 While the PYY response to a meal appeared flatter in the relatives versus controls 
(Fig. 1), the difference was not statistically significant when assessed with repeated measures 
ANOVA (p = 0.13). PYY area under the curve was not different between the groups 
(p = 0.34). 
 
 
7.2.1. Serum PYY levels in relation to GIR, fasting insulin, HOMA-B and serum adiponectin 
levels 
 There were no significant relationships between fasting serum PYY and BMI or other 
anthropometric indices in the overall group (% fat and BMI are shown in Fig. 2). Fasting 
serum PYY was significantly related to insulin sensitivity (GIR) (Fig. 2a). Moreover, there was 
an inverse relationship between fasting serum PYY and fasting serum insulin (Fig. 2b). There 
was also an inverse relationship between fasting serum PYY and HOMA-B (Fig. 2c) and a 
positive relationship with serum adiponectin (Fig. 2d). No correlations were observed between 
the area under the curve PYY and the area under the curve insulin response to a meal. 
 There was one relative subject with a BMI of 32 and low PYY levels in comparison to 
the rest of the relatives group (Fig. 2f). Correlation analyses were repeated with this subject 
removed and the relationship between fasting PYY and GIR (r = 0.659, p = 0.001), HOMA-B 
(r = − 0.549, p = 0.01) and adiponectin (r = 0.527, p = 0.02) remained, although the 
correlation between serum PYY levels and fasting serum insulin levels observed with analysis 
of the whole group was no longer significant (r = − 0.361, p = 0.12). 
 
7.3. Glucose-stimulated insulin secretion in islets of Langerhans from PYY knockout mice 
 The above data show that low fasting serum PYY levels inversely correlate with 
insulin sensitivity and increased insulin secretion. Moreover, PYY knockout mice exhibit high 
glucose-induced serum insulin levels (Boey et al., 2006). We therefore investigated whether 
the negative correlation between PYY levels and HOMA-B in our human study, as well as the 
high circulating insulin levels observed in PYY knockout mice, could be explained by effects 
of PYY deficiency on islet function. At a non-insulin-stimulating dose of glucose (2.8 mM), 
insulin secretion is comparable between islets taken from wild type and PYY KO mice (Fig. 
3). In contrast, at the insulin-stimulating doses of 16.7 mM and 25 mM glucose, islets taken 
from PYY KO mice secrete 3- to 4-fold more insulin than islets taken from wild types, 
significantly so at the higher glucose dose (Fig. 3). 
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8. Discussion 
             This study shows that, prior to the development of type 2 diabetes, women with a 
strong genetic propensity to type 2 diabetes have significantly lower fasting serum PYY levels 
than controls without any family history of diabetes. Moreover, fasting serum PYY levels, 
while not significantly correlated with any measures of adiposity, were positively correlated 
with insulin sensitivity and adiponectin, and negatively correlated with fasting insulin secretion 
as assessed by HOMA-B. Consistent with this, islets of Langerhans from PYY knockout mice 
were found to hyper-secrete insulin in response to high glucose concentrations. High fasting 
insulin is a better predictor of eventual development of type 2 diabetes than insulin resistance 
(Weyer et al., 2000). If PYY deficiency or low circulating levels of PYY contributes to the 
development of insulin hypersecretion and insulin resistance, this could be a putative cause 
of increased adiposity and insulin resistance with subsequent beta cell failure, as has been 
suggested in Pima Indians (Weyer et al., 2000). 
             The observation of a reduction in circulating PYY levels in relatives of people with 
type 2 diabetes compared to controls is important as these people are healthy and not yet 
significantly different to controls with respect to BMI, glycemia and hormonal or metabolic 
parameters. Thus, even in this normal but genetically “enriched” group, differences in 
circulating PYY levels could still be discerned, although, as stated, not all subjects are 
expected to have the genetic abnormalities. Since greater differences in circulating PYY 
levels have been detected between frankly obese and lean subjects in previous studies 
(Alvarez Bartlolome et al., 2002, Batterham et al., 2003 and Roth et al., 2005), it is 
conceivable that small, very long term deficiencies in PYY may contribute to the development 
of excess adiposity, but that subsequent differences in food intake and adiposity between  
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this subject removed and the relationship between fast-
ing PYY and GIR (rD 0.659, pD 0.001), HOMA-B
(rD¡ 0.549, pD 0.01) and adiponectin (rD0.527,
pD0.02) remained, although the correlation between
serum PYY levels and fasting serum insuli  levels
observed with analysis of the whole group was no longer
signiWcant (rD¡0.361, pD 0.12).
7.3. Glucose-stimulated insulin secretion in islets of 
Langerhans from PYY knockout mice
The above data show that low fasting serum PYY
levels inv rsely correlate with insulin sensitivity and
increased insulin secretion. Moreover, PYY knockout
mice exhibit high glucose-induced serum insulin levels
(Boey et al., 2006). We therefore investigated whether
the negative correlation between PYY levels and
HOMA-B in our human study, as well as the high cir-
culating insulin levels observed in PYY knockout mice,
could be explained by eVects of PYY deWciency on islet
function. At a non-insulin-stimulating dose of glucose
(2.8 mM), insulin secretion is comparable between islets
taken from wild type and PYY KO mice (Fig. 3). In
contrast, at the insulin-stimulating doses of 16.7 mM
and 25 mM glucose, islets taken from PYY KO mice
secrete 3- to 4-fold more insulin than islets taken from
wild types, signiWcantly so at the higher glucose dose
(Fi . 3).
Fig. 2. Correlations between fasting PYY levels (PYY0) and measures of insulin sensitivity and B cell function.
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lean and already obese subjects may exacerbate such differences. This study highlights an 
important association between PYY and insulin secretion in both humans and animals, with 
low circulating levels of PYY predisposing to high insulin secretion. 
 
  
            Our studies also show a relationship between PYY and insulin sensitivity in man 
(measured by the gold standard, the hyperinsulinemic clamp) that has previously been shown 
in rodents (van den Hoek et al., 2004). This is consistent with the direct relationship of PYY 
with adiponectin levels, which predicts both adiposity and insulin sensitivity (Hotta et al., 
2000 and Weyer et al., 2001). 
 In addition to our previous findings that PYY knockout animals exhibit elevated 
fasting or glucose-induced serum insulin levels in vivo (Boey et al., 2006), this study further 
demonstrates that lack of PYY alters the intrinsic properties of the Islets of Langerhans such 
that they hyper-secrete insulin in response to maximal stimulatory glucose concentrations. 
These islet isolation studies were performed in 13 week old chow-fed PYY knockout animals 
that were lean, showing that changes in islet function does not arise as a secondary effect of 
obesity. Indeed, a role for PYY in inhibiting glucose-stimulated insulin secretion has been 
demonstrated in vivo and in vitro in animals. Intravenously administered PYY has no effect on 
basal plasma insulin levels, but inhibits glucose-stimulated insulin secretion in mice (Bottcher 
et al., 1989 and Szecowka et al., 1983). In vitro studies also show that PYY dose-dependently 
inhibits glucose-stimulated but not basal insulin secretion (Karlsson and Ahren, 
1996 and Nieuwenhuizen et al., 1994). Studies using perfused islets isolated from rats 
suggest that this is a direct action of PYY on islets (Bertrand et al., 1992). This is supported 
by work on isolated mouse islets where PYY antiserum potentiates glucose-induced insulin 
secretion in culture (Karlsson and Ahren, 1996). However, the mechanisms by which PYY 
regulates insulin secretion still remain unclear. 
 Together, these data suggest that low circulating levels of PYY are linked to both 
insulin resistance and insulin hypersecretion. Although this pilot study was performed solely in 
female subjects to eliminate known variability between genders, further studies with a larger 
sample size including males would clearly be informative. Nonetheless, PYY may have an 
important regulatory role in the development of the metabolic abnormalities of type 2 
diabetes. We have previously described, in a similar group of diabetic relatives, a progressive 
decline in insulin secretion (by HOMA-B) over 6 years, which was predicted only by the gain 
in central fat, not by any increase in insulin resistance (Kriketos et al., 2003). Further study is 
indicated to determine whether there is a correlation between low fasting serum PYY levels 
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8. Discussion
This tudy s ows that, prior to the developme t of
type 2 diabetes, women with a strong genetic propensity
to type 2 diabetes have sig iWcantly lower fasting seru
PYY levels than controls without any family history of
diabetes. Moreover, fasting serum PYY levels, while not
signiWcantly correlated with any measures of adiposity,
were positively correlated with insulin sensitivity and
adiponectin, and negatively correlated with fasting insu-
lin secretion as assessed by HOMA-B. Consistent with
this, islets of Langerhans from PYY knockout mice were
found to hyper-secrete insulin in response to high glu-
cose concentrations. High fasting insulin is a better pre-
dictor of eventual development of type 2 diabetes than
insulin resistance (Weyer et al., 2000). If PYY deWciency
or low circulating levels of PYY contributes to the devel-
opment of insulin hypersecretion and insulin resistance,
this could be a putative cause of increased adiposity and
insulin resistance with subsequent beta cell failure, as has
been suggested in Pima Indians (Weyer et al., 2000).
The observation of a reduction in circulating PYY
levels in relatives of people with type 2 diabetes com-
p red t  con rols is important as these people are
ealthy and not yet s gniWcantly d Verent to controls
with respect to BMI, glycemia and hormonal or meta-
b lic p rameters. Thus, even in this normal but geneti-
cally “enric ed” group, diVerences in circulating PYY
levels could still be discerned, although, as stated, not all
subjects are expected to have the genetic abnormalities.
Since greater diVerences in circulating PYY levels have
been detected between frankly obese and lean subjects in
previous studies (Alvarez Bartlolome et al., 2002; Batter-
ham et al., 2003; Roth et al., 2005), it is conceivable that
small, very long term deWciencies in PYY may contribute
to the development of excess adiposity, but that subse-
quent diVerences in food intake and adiposity between
lean and already obese subjects may exacerbate such
diVerences. This study highlights an important associa-
tion between PYY and insulin secretion in both humans
and animals, with low circulating levels of PYY predis-
posing to high insulin secretion.
Our studies also show a relationship between PYY
and insulin sensitivity in man (measured by the gold
standard, the hyperinsulinemic clamp) that has previ-
ously been shown in rodents (van den Hoek et al., 2004).
This is consistent with the direct relationship of PYY
with adiponectin levels, which predicts both adiposity
and insulin sensitivity (Hotta et al., 2000; Weyer et al.,
2001).
In addition to our previous Wndings that PYY knock-
out animals exhibit elevated fasting or glucose-induced
serum insulin levels in vivo (Boey et al., 2006), this study
further demonstrates that lack of PYY alters the intrin-
sic properties of the Islets of Langerhans such that they
hyper-secrete insulin in response to maximal stimulatory
glucose concentrations. These islet isolation studies were
perf rmed in 13 week old chow-fed PYY knockout ani-
mals th t were lean, showing that changes in islet func-
tion does not arise as a secondary eVect of obesity.
Indeed, a role for PYY in inhibiting glucose-stimulated
insulin secretion has been demonstrated in vivo and
in vitro in animals. Intravenously administered PYY has
no eVect on basal plasma insulin levels, but inhibits glu-
cose-stimulated insulin secretion in mice (Bottcher et al.,
1989; Szecowka et al., 1983). In vitro studies also show
that PYY dose-dependently inhibits glucose-stimulated
but not basal insulin secretion (Karlsson and Ahren,
1996; Nieuwenhuizen et al., 1994). Studies using perfused
islets isolated from rats suggest that this is a direct action
of PYY on islets (Bertrand et al., 1992). This is sup-
ported by work on isolated mouse islets where PYY
antiserum potentiates glucose-induced insulin secretion
in culture (Karlsson and Ahren, 1996). However, the
mechanisms by which PYY regulates insulin secretion
still remain unclear.
Together, these data suggest that low circulating lev-
els of PYY are linked to both insulin resistance and insu-
lin hypersecretion. Although this pilot study was
perform d solely in female subjects to eliminate known
variability between genders, further studies with a larger
sample size including males would clearly be informa-
tive. Non theless, PYY may have an important regula-
tory role in the development of the metabolic
abnormalities of type 2 diabetes. We have previously
Fig. 3. Insulin secretion from isolated mouse pancreatic islets from
wild type and PYY knockout mice in the presence of 2.8, 16.7 and
25 mM glucose.
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and the subsequent fat gain, as well as the progressive decline in pancreatic function in these 
people at high risk for development of obesity and type 2 diabetes. 
 
Acknowledgements 
We thank Dr. Julie Ferguson (Garvan Institute) for veterinary advice, Eric Schmeid of the 
Garvan Institute Biological Testing Facility and Mia Akerfeldt for technical assistance. This 
research was supported by an Australian National Health and Medical Research Council 
(NHMRC) Peter Doherty Fellowship to L. Heilbronn, a NHMRC/Diabetes Australia Career 
Development Award to Amanda Sainsbury, a NHMRC RD Wright Career Development 
Fellowship to Adamandia Kriketos, a Grant by the Foundation for Prader-Willi Research and 
by the Diabetes Australia Research Trust. We thank Profs. Don Chisholm and John Eisman 
(Garvan Institute) for critical review of the manuscript. 
 
References 
Adrian, T.E., Ferri, G.L., Bacarese-Hamilton, A.J., Fuessl, H.S., Polak, J.M., Bloom, S.R., 
1985. Human distribution and release of a puta- tive new gut hormone, peptide YY. 
Gastroenterology 89, 1070– 1077.  
Adrian, T.E., Savage, A.P., Sagor, G.R., Allen, J.M., Bacarese-Hamilton, A.J., Tatemoto, K., 
Polak, J.M., Bloom, S.R., 1985. EVect of peptide YY on gastric, pancreatic, and biliary 
function in humans. Gastroenterology 89, 494–499.  
Alvarez Bartlolome, M., Borque, M., Martinez-Sarmiento, J., Aparicio, E., Hernandez, C., 
Cabrerizo, L., Fernandez-Represa, J.A., 2002. Peptide YY secretion in morbidly obese 
patients before and after vertical banded gastroplasty. Obesity Research 12, 324–327.  
Batterham, R.L., Cowley, M.A., Small, C.J., Herzog, H., Cohen, M.A., Dakin, C.L., Wren, 
A.M., Brynes, A.E., Low, M.J., Ghatzel, M.A., Cone, R.D., Bloom, S.R., 2002. Gut hormone 
PYY3¡36 physiologically inhibits food intake. Nature 418, 650–654.  
Batterham, R.L., Cohen, M.A., Ellis, S.M., Le Roux, C.W., Withers, D.J., Frost, G.S., Ghatei, 
M.A., Bloom, S.R., 2003. Inhibition of food intake in obese subjects by peptide YY3¡36. The 
New England Journal of Medicine 349, 941–948.  
Bertrand, G., Gross, R., Rove, M., Ahren, B., Ribes, G., 1992. Evidence for a direct inhibitory 
eVect of PYY on insulin secretion in rats. Pancreas 5, 595–600.  
Boey, D., Lin, S., Karl, T., Baldock, P., Lee, N., Enriquez, R., Couzens, M., Slack, K., 
Dallmann, R., Sainsbury, A., Herzog, H., 2006. Peptide YY ablation in mice leads to the 
development of hyperinsulinemia and obesity. Diabetologia 49, 1360–1370.  
Bottcher, G., Ahren, B., Lundquist, I., Sundler, F., 1989. Peptide YY: intrapancreatic 
localization and eVects on insulin and glucagon secretion in the mouse. Pancreas 4, 282–
288.  
Drivsholm, T., Olivarius, N., 2005. Routine diagnosis of Type 2 diabetes mellitus in general 
practice and hospitals: how do patients diVer? Diabetic Medicine 22, 336–339.  
English, P.J., Gillett, A., Dovey, T., Halford, J.C.G., Paterson, M.A., Bloom, S.R., Wilding, 
J.P.H., 2004. Evidence for PYY 3-36 resis- tance in Type 2 diabetes. Diabetic Medicine 21, 
36–108.  
Grandt, D., Schimiczek, M., Rascher, W., Feth, F., Shively, J., Lee, T.D., Davis, M.T., Reeve, 
J.R., 1994. Two molecular forms of pep- tide YY (PYY) are abundant in human blood: 
characterization of a radioimmunoassay recognising PYY 1-36 and PYY 3-36. Regulatory 
Peptides 51, 151–159.  
 
Boey	  et	  al.:	  	  Low	  serum	  PYY	  is	  linked	  to	  insulin	  resistance	  in	  first-­‐degree	  relatives	  of	  subjects	  with	  type	  2	  diabetes	  
Neuropeptides	  40(5):	  317-­‐324,	  2006	  
Halatchev, I.G., Cone, R.D., 2005. Peripheral administration of PYY3- 36 produces 
conditioned taste aversion in mice. Cell Metabolism 1, 159–168.  
Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., 
Kuriyama, H., Ouchi, N., Maeda, K., Nishida, M., Kihara, S., Sakai, N., Nakajima, T., 
Hasegawa, K., Muraguchi, M., Ohmoto, Y., Nakamura, T., Yamashita, S., Hanafusa, T., 
Matsuzawa, Y., 2000. Plasma concentrations of a novel, adipose-speciWc protein, 
adiponectin, in type 2 diabetic patients. Arteriosclerosis, Thrombosis and Vascular Biology 20, 
1595–1599.  
Kahn, C.B., Soeldner, J.S., Gleason, R.E., Rojas, L., Camerini-Davalos, R.A., Marble, A., 
1969. Clinical and chemical diabetes in oVspring of diabetic couples. New England Journal of 
Medicine 281.  
Karlsson, S., Ahren, B., 1996. A role for islet peptide YY in the regulation of insulin secretion. 
Acta Physiologica Scandinavica 157, 305– 306.  
Kim, B., Carlson, O., Jang, H., Elahi, D., Berry, C., Egan, J.M., 2005. Peptide YY is secreted 
after oral glucose administration in a gender-speciWc manner. Journal of Clinical 
Endocrinology and Metab- olism 90, 6665–6671.  
Kjorholt, C., Akerfeldt, M., Biden, T.J., Laybutt, D.R., 2005. Chronic hyperglycemia, 
independent of plasma lipid levels, is suYcient for the loss of ß-cell diVerentiation and 
secretory function in the db/db mouse model of diabetes. Diabetes 54, 2755–2763.  
Kriketos, A.D., Carey, D.G., Jenkins, A.B., Chisholm, D.J., Furler, S.M., Campbell, L.V., 2003. 
Central fat predicts deterioration of insulin secretion index and fasting glycaemia: 6-year 
follow-up of subjects at varying risk of Type 2 diabetes mellitus. Diabetic Medicine 20, 294–
300.  
Kriketos, A.D., GreenWeld, J.R., Peake, P.W., Furler, S.M., Denyer, G.S., Charlesworth, J.A., 
Campbell, L.V., 2004. InXammation, insulin resistance, and adiposity A study of Wrst-degree 
relatives of type 2 diabetic subjects. Diabetes Care 27, 2033–2040.  
Kriketos, A.D., Milner, K.-L., Denyer, G.S., Campbell, L.V., 2005. Is postprandial 
hypertriglyceridaemia in relatives of type 2 diabetic subjects a consequence of insulin 
resistance? European Journal of Clinical Investigation 35, 117–125.  
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., 
1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia 28, 401–411.  
Nieuwenhuizen, A.G., Karlsson, S., Fridolf, T., Ahren, B., 1994. Mechanisms underlying the 
insulinostatic eVect of peptide YY in mouse pancreatic islets. Diabetologia 37, 871–878.  
Peake, P.W., Kriketos, A.D., Denyer, G.S., Campbell, L.V., Charles- worth, J.A., 2003. The 
postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant 
subjects. International Journal of Obesity 27, 657–662.  
Pittner, R., Moore, C., Bhavsar, S., Gedulin, B., Smith, P., Jodka, C., Parkes, D., Peterniti, J., 
Srivastava, V., Young, A., 2004. EVects of PYY[3-36] in rodent models of diabetes and 
obesity. International Journal of Obesity 28, 963–971.  
Renshaw, D., Batterham, R.L., 2005. Peptide YY: a potential therapy for obesity. Current 
Drug Targets 6, 171–179.  
 
Roth, C.L., Enriori, P.J., Harz, K., WoelXe, J., Cowley, M.A., Reinehr, T., 2005. Peptide YY is 
a regulator of energy homeostasis in obese children before and after weight loss. The Journal 
Boey	  et	  al.:	  	  Low	  serum	  PYY	  is	  linked	  to	  insulin	  resistance	  in	  first-­‐degree	  relatives	  of	  subjects	  
Neuropeptides	  40(5):	  317-­‐324,	  2006	  	  
of Clinical Endocrinology and Metabolism 90, 6386–6391.  
Stock, S., Leichner, P., Wong, A.C.K., Ghatei, M.A., KieVer, T.J., Bloom, S.R., Chanoine, J., 
2005. Ghrelin, Peptide YY, Glucose- Dependent Insulinotropic Polypeptide, and Hunger 
Responses to a Mixed Meal in Anorexic, Obese, and Control Female Adolescents. Journal of 
Clinical Endocrinology and Metabolism 90, 2161–2168.  
Szecowka, J., Tatemoto, K., Rajamaki, G., Efendic, S., 1983. EVects of PYY and PP on 
endocrine pancreas. Acta Physiologica Scandinavica 119, 123–126.  
Torekov, S.S., Larsen, L.H., Glumer, C., Borch-Johnsen, K., Jorgen- sen, T., Holst, J.J., 
Madsen, O.D., Hansen, T., Pedersen, O., 2005. Evidence of an association between the 
Arg72 allele of the peptide YY and increased risk of type 2 diabetes. Diabetes 54, 2261–
2265.  
van den Hoek, A.M., Heijboer, A.C., Corssmit, E.P.M., Voshol, P.J., Romijn, J.A., Havekes, 
L.M., Pijl, H., 2004. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-
fat diet. Diabetes 53, 1949–1952.  
Vrang, N., Madsen, A.N., Tang-Christensen, M., Hansen, G. and Larsen, P.J., 2006. PYY3-
36 reduces food intake and body-weight and improves insulin sensitivity in rodent models of 
diet-induced obesity. American Journal of Physiology doi:10.1152/ ajregu.00726.2005.  
Weyer, C., Hanson, R.L., Tataranni, P.A., Bogardus, C., Pratley, R.E., 2000. A high fasting 
plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: 
evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49, 2094– 2101.  
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Prat- ley, R.E., Tataranni, 
P.A., 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with 
insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 86, 
1930–1935.  
 
 
 
 
 
